The bill amends title XVIII of the Social Security Act to require germline mutation testing for individuals with a personal or family history suspicious for hereditary cancer, and to cover certain cancer risk-reducing surgeries and evidence-based screenings when guidelines indicate benefit. It further defines what constitutes germline mutation testing and sets how often testing and related preventive services should be reviewed under Medicare, tying coverage to established clinical practice guidelines.
The amendments are designed to ensure high-risk individuals have access to early detection and prevention measures, with implementation starting on enactment.
By anchoring testing and preventive services to guidelines developed by nationally recognized oncology organizations, the bill aims to standardize when Medicare covers these services and how frequently they are offered. It also expands the set of covered interventions to include annualized screenings and genetic testing when evidence supports benefit, potentially shifting downstream care patterns toward prevention and early intervention.
At a Glance
What It Does
Adds a new coverage pathway for germline mutation testing for individuals with personal or family histories suspicious for hereditary cancer, and creates a defined testing standard (nnn) tied to evidence-based guidelines. It also adds coverage for risk-reducing surgeries and increases coverage frequency for screenings based on guidelines.
Who It Affects
Medicare beneficiaries at high genetic risk, Medicare Administrative Contractors, oncology practices and genetic testing labs, and health systems implementing these coverage changes.
Why It Matters
Establishes a standards-based approach to testing and preventive care for hereditary cancer, aiming to catch cancers early and reduce incidence through guideline-directed interventions.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The act amends Medicare law to ensure that people with a personal or family history suggesting a hereditary cancer risk can receive genetic testing for germline mutations through Medicare. It defines what counts as germline mutation testing and requires that the testing align with guidelines from major oncology organizations, choosing the least restrictive guideline when there is a conflict.
The bill also authorizes coverage of risk-reducing surgeries for those whose risk profile is supported by evidence-based guidelines.
Additionally, the legislation broadens coverage for evidence-based cancer screenings for high-risk individuals. It requires Medicare to adjust frequency limitations to reflect guideline-directed recommendations, not allowing fewer than annual screenings where appropriate.
The changes apply to items and services furnished on or after enactment, and they rely on established clinical practice guidelines to determine what is necessary for treatment and prevention.Taken together, these provisions are intended to improve access to genetic testing and preventive interventions for people most at risk of hereditary cancers, with the expectation that earlier detection and prevention will improve outcomes and potentially reduce long-term treatment costs.
The Five Things You Need to Know
The bill adds germline mutation testing coverage for individuals with personal or family history suggesting hereditary cancer.
It defines germline mutation testing through guidelines from major oncology organizations and uses a least-restrictive guideline when conflicts exist.
It authorizes coverage of risk-reducing surgeries when guidelines indicate reduced cancer risk.
It requires increasing frequency of evidence-based screenings (e.g.
mammography, MRI, colonoscopy, PSA) for high-risk individuals.
Coverage applies to testing and screenings furnished on or after enactment date.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
This act may be cited as the Reducing Hereditary Cancer Act of 2025. The short title provides a formal name for the legislation to guide implementation and reference in policy discussions.
Germline mutation testing coverage and definitions
Section 1861(s)(2) is amended to add a new subparagraph (KK) requiring germline mutation testing for individuals with a personal or family history of hereditary cancer. It also adds a new definition (nnn) for “germline mutation testing,” anchoring it to testing that follows evidence-based guidelines developed by nationally recognized oncology organizations and, when guidelines conflict, selects the least restrictive option as determined by the Medicare administrative contractor. This section formalizes testing in Medicare coverage and ties it to established clinical guidelines.
Coverage of risk-reducing surgeries
New subsection (p) to 1862 authorizes coverage of risk-reducing surgeries for individuals described in 1861(s)(2)(KK) when such surgeries are deemed reasonable and necessary under evidence-based guidelines. The provision aligns surgical preventive care with guideline-based risk reduction, ensuring coverage is conditional on demonstrated benefit.
Coverage of evidence-based screenings
Section (q) to 1862 expands coverage of evidence-based screenings for individuals with a germline mutation, allowing frequency and other coverage limitations to be adjusted to match current guidelines, but not less than annual, where indicated. It explicitly includes mammography, breast MRI, colonoscopy, PSA testing, and other screening modalities recommended by guidelines for high-risk populations, with implementation tied to national oncology organizations' guidance. The section also integrates 1862(q) into related Medicare provisions for consistency.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Patients and families with a history of hereditary cancer who stand to benefit from earlier detection and preventive options.
- Oncologists, genetic counselors, and genetic testing labs who will see clearer coverage criteria and stronger guideline-driven pathways.
- Hospitals and cancer centers that implement standardized testing and preventive protocols, potentially reducing late-stage cancer treatment costs.
- Medicare program staff and MACs who will administer a clearer, guideline-driven coverage framework.
Who Bears the Cost
- Medicare program expenditures related to expanded coverage for testing and increased preventive services.
- Healthcare providers and facilities that must align billing, documentation, and care pathways with the new guidelines, potentially increasing administrative workload.
- Genetic testing laboratories to scale operations and quality assurance for higher testing volumes.
Key Issues
The Core Tension
Expanding Medicare coverage for germline testing and preventive care requires relying on evolving clinical guidelines to define what is covered and how often. That creates a tension between broad access to potentially life-saving interventions and the cost and logistical realities of implementing guideline-directed care across diverse health systems.
The bill’s reliance on guidelines from nationally recognized oncology organizations means its practical effects depend on how those guidelines harmonize. The provision granting the Medicare contractor the authority to select the least restrictive guideline when conflicts exist could lead to variability in testing and coverage across regions or plans.
The expansion of screening frequency is tied to guideline recommendations, which may evolve and influence future costs and patient access. A key tension is balancing broad access to testing and preventive care with the budgetary impact on the Medicare program and on the pace at which clinics can adapt to new documentation and reporting requirements.
As with many coverage expansions, there is potential for uneven uptake if providers or patients face barriers to obtaining test results, genetic counseling, or timely access to high-volume screening services.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.